Dr. Samuels is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3815 N. Schreiber Way
Suite 101
Coeur D Alene, ID 83815Phone+1 208-755-2804Fax+1 208-765-0277
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1984 - 1988
- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1983 - 1984
- University of WitwatersrandRegistrar, Internal Medicine, 1981 - 1983
- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1979 - 1981
- University of Zimbabwe Huggins SOMClass of 1976
Certifications & Licensure
- ID State Medical License 2004 - 2025
- WA State Medical License 2012 - 2023
- IL State Medical License 1985 - 2005
- PA State Medical License 1980 - 1998
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
- Join now to see all
Clinical Trials
- Toremifene in Treating Patients With Desmoid Tumors Start of enrollment: 1991 Jul 01
- Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer Start of enrollment: 2000 Mar 01
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Start of enrollment: 2012 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsOsteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?Caleb Kim, Lara E Davis, Catherine M Albert, Brian Samuels, Jesse L Roberts
Cancers. 2023-10-19 - 22 citationsAssociation of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.Scott M. Schuetze, Vanessa Bolejack, Dafydd G. Thomas, Margaret von Mehren, Shreyaskumar Patel
JAMA Oncology. 2018-06-01 - 65 citationsResults of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcomaBrian L. Samuels, Sant P. Chawla, Neeta Somaiah, Arthur P. Staddon, Keith M. Skubitz
Cancer. 2017-12-01
Journal Articles
- SARC 009: Phase II study of dasatinib in patients with previously-treated, high-grade advanced sarcomaScheutze SM, Wathen K, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb D, Thomas D, Chugh R, Reinke D, Baker LH, Cancer, 1/1/2016
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide ex...B. L. Samuels, S. Chawla, S. Patel, M. von Mehren, J. Hamm, P. E. Kaiser, S. Schuetze, J. Li, A. Aymes, G. D. Demetri, Ann Oncol, 1/1/2013
- Sarcoma Alliance for Research through Collaboration (SARC) Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Rese...Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH, Clin Cancer Res, 1/1/2010
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Phase II Study of Pazopanib in Patients With Advanced Intermediate or High-Grade LiposarcomaB. Samuels, S. Chawla, N. Somaiah, A, Staddon, K. Skubitz, K. Mulvey, M. Milhelm, P. Kaiser, D. Portnoy, D. Preibat, M. Walker, E. Stepanski, Connective Tissue Oncology Society Meeting, 1/1/2015
- SARC021: A Randomized Phase 3, Multicenter, Open-label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced U...S. Chawla, K. Ganjoo, L. Cranmer, S. Schuetze, B.A. Van Tine, N. Somaiah, A. Staddo, M. Milhem, B. Samuels, et al, Connective Tissue Oncology Society Meeting, 1/1/2012
- A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)J. C. Trent, K. Wathen, M. von Mehren, B. L. Samuels, A. P. Staddon, E. Choy, J. E. Butrynski, R. Chugh, W. A. Chow, D. A. Rushing, C. A. Forscher, L. H. Baker, S. Sch..., Proc Am Soc Clin Oncol, 1/1/2011
- Join now to see all
Press Mentions
- When Checking the Mailbox Is TerrifyingApril 7th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: